Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma

NCT06277154 is registered in ClinicalTrials.gov with HRYZ Biotech Co. as lead sponsor.

NCT NCT06277154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06277154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
Lead sponsor
HRYZ Biotech Co.
Phase
Phase 2
Overall status
Recruiting
Start date
February 21, 2024
Completion date
February 28, 2027
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma, desmoplastic small round cell tumor, endometrial stromal sarcoma, epithelioid sarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, malignant peripheral nerve sheath tumors, pleomorphic rhabdomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma